Abstract

ABSTRACT The gut microbiome has recently emerged as an important regulator of insulin resistance and abdominal obesity. The tryptophan metabolite generated by the gut microbiome, indoleproprionic acid (IPA) has been shown to predict the onset of type 2 diabetes. IPA is a metabolite produced by gut microbes from dietary tryptophan that exhibits a high degree of inter-individual variation. The microbiome composition parameters that are associated with circulating levels of this potent anti-oxidant have however not been investigated to date in human populations. In 1018 middle-aged women from the TwinsUK cohort, we assessed the relationship between serum IPA levels and gut microbiome composition targeting the 16S rRNA gene. Microbiome alpha-diversity was positively correlated with serum indoleproprionic acid levels (Shannon Diversity: Beta[95%CI] = 0.19[0.13;0.25], P = 6.41 × 10−10) after adjustment for covariates. Sixteen taxa and 12 operational taxonomic units (OTUs) associated with IPA serum levels. Among these are positive correlations with the butyrate-producing Faecalibacterium prausnitzii, the class Mollicutes and the order RF39 of the Tenericutes, and Coprococcus Negative correlations instead were observed with Eubacterium dolichum previously shown to correlate with visceral fat mass and several genera in the Lachnospiraceae family such as Blautia and Ruminococcus previously shown to correlate with obesity. Microbiome composition parameters explained ~20% of the variation in circulating levels of IPA, whereas nutritional and host genetic parameters explained only ~4%. Our data confirm an association between IPA circulating levels and metabolic syndrome parameters and indicate that gut microbiome composition influences IPA levels.

Highlights

  • Indoleproprionic acid (IPA) is an antioxidant predictive of a lower risk of developing type 2 diabetes (T2D).[1]

  • We first tested whether IPA levels were associated with clinical parameters related to metabolic syndrome in our cohort and we find that it is

  • In this study we have investigated for the first time in humans, the relationship between IPA circulating levels, gut microbiome composition and metabolic health in 1018 women

Read more

Summary

Introduction

Indoleproprionic acid (IPA) is an antioxidant predictive of a lower risk of developing type 2 diabetes (T2D).[1] De Mello et al.[1] compared IPA levels in individuals with impaired glucose tolerance, some of whom developed T2D over 15 years. Higher IPA levels are associated with reduced likelihood of developing T2D and this was further replicated in a Swedish population.[1]. Indolepropionic acid is a deamination product of the amino acid tryptophan. It accumulates in human serum, exhibits a high degree of interindividual variation[2] and regulates gastrointestinal barrier function via its interaction with the pregnane X receptor (PXR).[3]. Dietary and genetic factors have been implicated in the circulating levels of this compound in humans, and the gut microbes linked to IPA have been studied in mice

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call